News | Atrial Fibrillation | Dave Fornell, Editor
May 15, 2019 — Renal artery denervation (RDN) was found to be safe when employed with pulmonary vein isolation (PVI) to ...
May 15, 2019
News | EP Lab
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, including ...
May 15, 2019
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...
May 15, 2019Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
Feature | HRS | Dave Fornell, Editor
May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm ...
May 15, 2019
Technology | Ventricular Assist Devices (VAD)
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD premarket approval (PMA) labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days.
May 14, 2019
News | Atrial Fibrillation | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vein ...
May 14, 2019Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus statement reflecting a worldwide updated review of the indications, techniques and outcomes of catheter ablation of ventricular arrhythmias (VAs). The expert consensus statement was presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.
May 14, 2019
News | Cardiac Diagnostics
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and management of arrhythmogenic cardiomyopathy (ACM), including findings on genetics and disease mechanisms. Recommendations included in the 2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy were presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.
May 14, 2019
News | EP Lab
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), such ...
May 14, 2019Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the ...
May 13, 2019
News | EP Lab
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their ...
May 13, 2019
News
May 13, 2019 – A first-in-human pilot study of Medtronic's investigational Extravascular Implantable Cardioverter ...
May 13, 2019Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News | Atrial Fibrillation
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce atrial ...
May 13, 2019
News | Atrial Fibrillation
May 13, 2019 — A digital screening for atrial fibrillation (AFib or AF) successfully monitored more than 60,000 ...
May 13, 2019
News | Leads Implantable Devices
BioTrace Medical Inc. announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing.
May 13, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now